Beta-Lactam Antibiotics as A Possible Novel Therapy for Managing Epilepsy and Autism, A Case Report and Review of Literature
نویسندگان
1 1. Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences, Shiraz, Iran 2. Department of Psychiatry, Shiraz University of Medical Sciences, School of Medicine, Shiraz, Iran 3. Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
2 4. Professor of Psychiatry, School of Medicine, Deakin University, Melbourne, Australia 5. Professorial Research Fellow, The Florey Institute of Neuroscience and Mental Health, Orygen Research Centre and the Department of Psychiatry, University of Melbourne, Melbourne, Australia
doi
10.22037/ijcn.v9i1.5493چکیده
How to Cite This Article: Ghanizadeh A, Berk M. Beta-Lactam Antibiotics as A Possible Novel Therapy for Managing Epilepsy and Autism, A Case Report and Review of Literature. Iran J Child Neurol. 2015 Winter;9(1):99-102.AbstractAutism is a disorder of unknown etiology. There are few FDA approved medications for treating autism. Co-occurring autism and epilepsy is common, and glutamate antagonists improve some symptoms of autism. Ceftriaxone, a beta-lactam antibiotic, increases the expression of the glutamate transporter 1 which decreases extracellular glutamate levels. It is hypothesized that modulating astrocyte glutamate transporter expression by ceftriaxone or cefixime might improve some symptoms of autism. This case report of a child with autism and epilepsy suggests a decrease in seizures after taking cefixime.References Selassie AW, Wilson DA, Martz GU, Smith GG, Wagner JL, Wannamaker BB. Epilepsy beyond seizure: a population-based study of comorbidities. Epilepsy Res 2014;108(2): 305-315.Sansa G, Carlson C, Doyle W, Weiner HL, Bluvstein, Barr W, et al. Medically refractory epilepsy in autism. Epilepsia 2011; 52(6): 1071-1075.Ghanizadeh A. Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. Dis Markers; 2013;35(5): 281-286.Yamada T, Kawahara K, Kosugi T, Tanaka M.Nitric oxide produced during sublethal ischemia is crucial for the preconditioning-induced down-regulation of glutamate transporter GLT-1 in neuron/astrocyte co-cultures. Neurochem Res 2006:31(1): 49-56.Zeng, LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC, et al. Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007; 28(2): 184-196.Zeng LH, Bero AW, Zhang B, Holtzman D. M. , Wong M. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis 2010; 37(3): 764-771.Nizzardo M, Nardini M, Ronchi D, Salani S, Donadoni C, Fortunato F, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Experimental Neurology 2011; 229: 214–225.Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H and T. Matsuda. Non-Invasive Evaluation of the GABAergic/Glutamatergic System in Autistic Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3 Tesla Instrument. J Autism Dev Disord 2010 Apr;41(4):447-54. doi: 10.1007/s10803-010-1065- 0.Polleux, F. and J. M. Lauder. Toward a developmental neurobiology of autism. Ment Retard Dev Disabil Res Rev 2004;10(4): 303-317.Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci 2010;30(15): 5346-5356.Ghanizadeh A. Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflammation 2010;7(1): 58.Ghanizadeh A. Transplantation of GABAergic cell line as a novel hypothesized treatment for autism. Epilepsy & Behavior 2010;19(4): 664.Kim SY, Jones TA. The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats. Restor Neurol Neurosci 2013;31(1):87-97. doi: 10.3233/RNN-2012-120245.Ghanizadeh A.Could fever and neuroinflammation play a role in the neurobiology of autism? A subject worthy of more research. Int J Hyperthermia 2011;27(7): 737-738.Ghanizadeh A. May lovastatin target both autism and epilepsy? A novel hypothesized treatment. Epilepsy Behav 2011;20(2): 422.Ghanizadeh A. Hydrogen as a novel hypothesized emerging treatment for oxidative stress in autism. Eur Rev Med Pharmacol Sci 2012;16(9): 1313-1314.Ghanizadeh A. Physical exercise and intermittent administration of lactulose may improve autism symptoms through hydrogen production. Med Gas Res 2012;2(1): 19.Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi MR, Hassanzadeh E, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013 Jan;225(1):51-9. doi: 10.1007/s00213-012- 2796-8. Epub 2012 Jul 11.Wang DD, Englot DJ, Garcia PA, Lawton MT, Young WL. Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav 2012;24(3): 314-318.Librizzi L, Noe F, Vezzani A, Curtis M, Ravizza T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012;72(1): 82-90.Gasior MK, Nieoczym SD, Wlaz P. Clavulanic acid does not affect convulsions in acute seizure tests in mice. J Neural Transm 2012;119(1): 1-6.Beheshti Nasr SM, Moghimi A, M. Mohammad-Zadeh M, Shamsizadeh A and Noorbakhsh SM. The effect of minocycline on seizures induced by amygdala kindling in rats. Seizure 2013;22(8): 670-674.Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR,McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 2007;191(1): 141-147.Thabet F, Al Maghrabi M, Al Barraq A, Tabarki B. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care 2009;10(3): 347-351.
